Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
Technology Review reports that animals given large gene therapies doses have suffered fatal side effects.
Pacific Standard notes that gene therapy has become more of a reality, but with a high price tag.
Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.
A nonprofit group argues that Spark Therapeutics' Luxturna is too expensive, Forbes reports.
University of Pittsburgh-led team finds that gene therapy could treat mice with type 1 diabetes for a few months, the Los Angeles Times reports.
Spark Therapeutics sets the price of its gene therapy Luxturna at $850,000, CNBC reports.
University of California, Los Angeles, researchers investigate gene therapy as an HIV treatment, Gizmodo reports.
The Associated Press writes that gene therapy has now shown that it could be harnessed to treat disease.
The US Food and Drug Administration has approved Spark Therapeutics' Luxturna for retinal dystrophy.
Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.
King's College London researchers examine the influence of school type and genetics on academic achievement.
FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.
In Science this week: early life experience influence somatic variation in the genome, and more.